COSTOYaNIE SISTEMY OSTEOPROTEGERIN (OPG) - LIGAND RETsEPTORA-AKTIVATORA YaDERNOGO FAKTORA KAPPA-V (RANKL)u patsientov s diabeticheskoy osteoartropatiey i mediakal'tsinozom arteriy nizhnikh konechnostey
Abstract
About the Authors
M. V. YaROSLAVTsEVAI. N. UL'YaNOVA
G R GALSTYaN
A. V. IL'IN
L. V. NIKANKINA
O. V. REMIZOV
References
1. Беневоленская Л. И. / Руководство по остеопорозу. // - М.: БИНОМ. Лаборатория знаний, 2003. - с.82
2. Шварц Г. Я. / Молекулярно-биологические основы создания новых лекарственных средств для лечения остеопороза: 1. Остеопротегерин, ЛОПГ (RANKL) и RANK: физиологический механизм (ы) регуляции костной резорбции. Обзор литературы. // Остеопороз и остеопатии № 2, 2003. - с.21-22
3. Abedin M., Tintut Y., Demer L. / Vascular calcification: mechanisms and clinical ramifications. // Aterosclerosis, thrombosis, and vascular biology, 2004; 24; 1164-1170.
4. Browner W. S., Lui L. Y., Cummings S. R. / Associations of serum osteoprotegerin levels wits diabetes, stroke, bone density, fractures, and mortality in elderly women. // J Clin Endocrinol Metab 2001; 86: 631-37.
5. Hofbauer L., Shoppet M. / Osteoprotegerin: a link between osteoporosis and arterial calcification? // The Lancet. Vol.358, July 28, 2001.
6. Hofbauer L. C., Shui C., Riggs B. L., et al. / Effects of immunosuppressants on receptor activator of NF-kB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cell. // Biochem Biophys Res Commun 2001; 280:334-39.
7. Jeffcoate W. / Vascular calcification and osteolysis in diabetic neuropathy - is RANK-L the missing link? // Diabetologia 2004. 47:1488-1492.
8. Malyankar U. M., Scatena M., Suchland K. L., Yun T. J., Clarc E. A., Giachechelli C. M. / Osteopronegerin is an aß-induced, NF-kB-dependent survival factor for endothelial cells. // J. Biol.Chem 2000; 275: 20959-62.
9. Min H., Morony S., Sarosi I., et. al. / Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. // J. Exp Med 2000; 192: 463-74.
10. Schoppet M., Sattler A.N.M., Schaefer J. R., Herzum M., Maisch B., Hofbauer L. C. / Increased osteoprotegerin serum levels in men with coronary artery disease. // J. Clin Endocrinol. Metabol. 2003, 88: 1024-1028.
11. Simmonet W. S., Lacey D. L., Dunstan C. R., et al. / Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. // Cell 89: 309-319.
12. Tsuda E., Goto M., Mochizuki S. et al. / Isolation of a novel cytokine from human fibroblasts that specifically inhibites the osteoclastogenesis // Biochem. Biophys. Res. Comm. 1997 V.234 P. 137-142
13. Yasuda H., Shima N., Nakagawa N., et al. / Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. // 1998, Endocrinology 39:1329-1337.
Review
For citations:
YaROSLAVTsEVA M.V., UL'YaNOVA I.N., GALSTYaN G.R., IL'IN A.V., NIKANKINA L.V., REMIZOV O.V. COSTOYaNIE SISTEMY OSTEOPROTEGERIN (OPG) - LIGAND RETsEPTORA-AKTIVATORA YaDERNOGO FAKTORA KAPPA-V (RANKL)u patsientov s diabeticheskoy osteoartropatiey i mediakal'tsinozom arteriy nizhnikh konechnostey. Osteoporosis and Bone Diseases. 2008;11(1):9-13.
Email this article 
